Iniparib: Additional Phase II data

Additional data from a single-arm, open-label, U.S. Phase II trial in 32 evaluable patients showed that IV BSI-201 plus gemcitabine and carboplatin produced an ORR of 25%. The most common adverse events were neutropenia, thrombocytopenia, nausea, anemia, small intestinal obstruction, abdominal pain and fatigue. The trial plans to enroll 48 patients with epithelial ovarian carcinoma, fallopian tube cancer or primary peritoneal carcinoma. Patients are receiving gemcitabine and carboplatin on days 1 and 8 of each 21-day cycle, plus 5.6 mg/kg BSI-201 on days 1, 4, 8 and 11 of each cycle. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...